Methods and Principles in Medicinal Chemistry Series

Spanning over 20 years, Wiley’s “Methods and Principles in Medicinal Chemistry” series has become the main source of information in the Medicinal Chemistry community.

Since the first volume published in 1993, this prestigious series has focused on topical volumes about cutting-edge concepts and technologies, broadening the view of medicinal chemists and acquainting them with ever novel approaches towards better and innovative drugs.

Many of the books in this are available in print and online, with the older titles only available online. All volumes in the series are also available as an online book series.

To view all current titles in the series, please visit www.wiley.com/go/medchemseries
Established in 1993 by Raimund Mannhold, Povl Krogsgaard-Larsen and Hendrik Timmerman, *Methods and Principles in Medicinal Chemistry* has become a main source of information in the Medicinal Chemistry community and beyond. Authors and editors in the series have come from the pharmaceutical industry as well as from academic institutions, fostering a more active exchange between these realms.

From the very beginning, the series has focused on topical volumes about cutting-edge concepts and technologies, broadening the view of medicinal chemists and acquainting them with ever novel approaches towards better and innovative drugs.

Find out more about the current Series Editors below.

**Raimund Mannhold** is an emeritus Professor for Molecular Drug Research at the University of Düsseldorf. His primary interests lie with QSAR studies and related methods. He is a founding editor of the book series and serves on the editorial boards of several journals in Medicinal Chemistry and Drug Design.

**Helmut Buschmann** started his career in pharmaceutical research at Grünenthal in Aachen, moving on to become Research Director of Esteve in Barcelona. In parallel he has been teaching medicinal chemistry at Aachen University. He is currently a member of Pharma Consulting Aachen and CSO of Savira Pharmaceuticals.

**Jörg Holenz** is the director of discovery and preclinical sciences for AstraZeneca’s neuroscience unit in Boston, where he is responsible for driving R&D projects via academic and industry collaborative networks. During his career, he worked predominantly with targets in the pain and neuroscience disease areas.